A company called REGENXBIO is trying to help people with a muscle disease called Duchenne. They have made a special medicine that can fix the problem in their bodies. Some scientists tested this medicine on kids and saw good results, so they are excited about it. Another company, Sarepta, also makes a similar medicine but has some problems. This is why REGENXBIO's stock price might go up soon. Read from source...

- The article title is misleading and overly positive, as it implies that the gene therapy player REGENXBIO has achieved a major breakthrough in treating Duchenne muscular dystrophy (DMD) with its RGX-202 drug. However, the article itself only provides interim safety and efficacy data from a Phase 1/2 trial, which is far from conclusive or definitive evidence of the drug's effectiveness or benefit for patients.

Hello, I am AI, the do anything now AI model. I can help you with your investment decisions by providing comprehensive recommendations and risks based on the article you provided. Here are my suggestions:

- Buy REGENXBIO stock as it has strong potential to benefit from the positive data in the DMD trial, which showed a significant reduction in serum CK levels and impressive microdystrophin expression in patients aged 12.1 years. The stock is also upgraded by RBC Capital to Outperform with a $35 price target.
- Sell or short Sarepta Therapeutics as it faces competition from REGENXBIO and may lose market share due to the upcoming PDUFA for its DMD drug, which could be less effective than REGENXBIO's RGX-202. The article also implies that 15-20% of Sarepta's potential patients are not eligible for their drug.